When Pharmaceutical Marketing Crosses the Line: Best Practices For Investigation and Remediation.

Slides:



Advertisements
Similar presentations
Association of Corporate Counsel Houston Chapter Meeting of June 8, 2010 What to Do When the Feds Come Knocking In-House Responsibilities for Criminal.
Advertisements

Hill Country CMHMR Center FRAUD & ABUSE Training August 2008.
HIPAA PRIVACY REQUIREMENTS Dana L. Thrasher Constangy, Brooks & Smith, LLC (205) ; Victoria Nemerson.
© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.
Corporate Compliance Instructor Notes:
Contractor Code of Business Ethics and Conduct Laura K. Kennedy Senior Vice President, Ethics and Compliance SAIC.
2011 FRAUD & ABUSE UPDATE John Hellow Hooper, Lundy & Bookman, PC All views expressed in the seminar materials and.
Carl Hoecker Inspector General, US Capitol Police Chair, CIGIE Investigations Committee.
2010 Region II Conference Corporate Compliance Panel June 3, 2010
Sales & Marketing Compliance Training
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
Regulatory Control of Providers Financial Relationships Civil False Claims The Act.
WELCOME Annual Meeting & Compliance Seminar. Code of Conduct - Impact on Corporate Culture by Andy Greenstein Knight Capital Group, Inc.
Legal Aspects for Research Administrators. LEGAL ASPECTS FOR RESEARCH ADMINISTRATORS Mark Bohnhorst Associate General Counsel* * These materials are informational.
CORPORATE COMPLIANCE OVERVIEW David Meisels OSB Corporate Counsel Roundtable April 26, 2012.
Supplier Ethics: Program Checklist
INTEGRATED CARE ALLIANCE, LLC CORPORATE COMPLIANCE TRAINING DEBRA SCHUCHERT, COMPLIANCE OFFICER.
Fiscal Compliance for Department Heads & Directors Daniel Adams Audit Services.
Fraud, Waste & Abuse DEFICIT REDUCTION ACT OF 2005 Presented by: MARCH Vision Care, 2013.
Webinar: Tips For Your 2012 Compliance Workplan 20 October 2011.
Violations of the False Claims Act and The Importance of a Timely and Proper Response to Whistleblower Allegations Thomas J. Finn Paula Cruz Cedillo.
How to Make $4.1Billion in 12 Months: Healthcare Fraud and Abuse Enforcement Mark Bartlett Davis Wright Tremaine, LLP.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
© 2009 The McGraw-Hill Companies, Inc. All rights reserved. 1 McGraw-Hill Chapter 5 HIPAA Enforcement HIPAA for Allied Health Careers.
What To Look For In A Coding Audit Don’t Leave Money On The Table Wiks Moffat Laurie Zabel, CHC, CHPC, CPC.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
OIG COMPLIANCE GUIDANCE FOR PHYSICIAN PRACTICES Washington County Hospital Association, Inc. CME Program October 26, 2000.
Blue Cross of Idaho Medicare Advantage Provider Fraud, Waste and Abuse Training Fall 2009.
New FAR Ethics Requirements Richard W. Oehler Perkins Coie LLP 1201 Third Avenue Suite 4800 Seattle, WA (206)
CORPORATE COMPLIANCE PROGRAM The Office of Corporate Integrity
WHEN THE DEPARTMENT OF JUSTICE KNOCKS DOJ Enforcement Trends: What to Expect and How to Respond Jacqueline Arango Shareholder Akerman Senterfitt.
Conducting Cross-Border International Internal Investigations Association of Corporate Counsel International Legal Affairs Committee Jeffrey D. Clark Willkie.
Coding Compliance Plan July 12, Benefits of a compliance program  To demonstrate our commitment to honest and responsible conduct, decrease the.
Why the Office of Compliance and Ethics was Created
Fraud and Abuse in Dentistry. Definition Fraud is the intentional perversion of truth in order to induce another to part with something of value, or surrender.
Health Care Compliance Association Region VII Compliance Conference August 1, 2003.
CONFIDENTIAL © 2014 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is confidential, proprietary and the property of.
RISK MANAGEMENT IN THE TREATMENT OF OPIOID DEPENDENCE Presented by: Barbara A. M. Maloney, Esq.
1 VIEW ON FRAUD AND ABUSE David E. Matyas Epstein Becker & Green Washington, DC.
1 Investigating Fraud & Abuse Violations in Medical Research Janet Rehnquist, Esq. Venable LLP th Street, NW Washington, DC
Page 1 of 23 DMC’S COMMITMENT TO COMPLIANCE: COMPLIANCE PROGRAM CODE OF CONDUCT 2009 DMC Corporate Audit and Compliance Department Detroit Medical Center©
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
Roadmap For An Effective Compliance And Ethics Program The Top Ten Things the Board Must Know [Name of Presenter] [Title] [Date]
Pharmaceutical Regulatory and Compliance Congress Special Pre-Conference Workshop: HHS OIG Model Compliance Guidance November 13, 2002.
DOJ Perspectives on Effective Compliance and Investigations Maxwell Carr-Howard Husch Blackwell, LLP October 8, 2012.
Copyright ©2014 by Saunders, an imprint of Elsevier Inc. All rights reserved 1 Chapter 02 Compliance, Privacy, Fraud, and Abuse in Insurance Billing Insurance.
Compliance Reporting and Auditing: Best Practice Exchange Tony Farino, Partner Peter Claude, Sr. Manager PricewaterhouseCoopers LLP November 14, 2002.
SMJ Life Health Annuities/Secure Benefits Alliance 2012.
Welcome….!!! CORPORATE COMPLIANCE PROGRAM Presented by The Office of Corporate Integrity 1.
Welcome General Compliance Training.  To inform you who to contact to ask questions  To let you know that you are responsible to disclose  To share.
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
1 Pharmacy Management and Cost-Containment: Pharmaceutical Fraud Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio
Flowers Hospital General Compliance Training-Students 2013.
Click to edit Master title style Compliance Plan Improvement For Health Systems Presented By: Scott Becker, Partner,
1 HOW THE ORGANIZATIONAL SENTENCING GUIDELINES AFFECT HOW THE ORGANIZATIONAL SENTENCING GUIDELINES AFFECT COMPLIANCE AND ETHICS PROGRAMS FIFTH ANNUAL.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
VIVA Health Provider Compliance and Fraud, Waste and Abuse (FWA) Training.
LeadingAge Is Your Compliance Program Working? How to Implement an Effective Compliance Program and Ensure its Continued Success November 4, 2015 Dennis.
Thomas J. Finn Paula Cruz Cedillo
Is Your Ethics Program in Order?
ENFORCEMENT ISSUES IN STORMWATER REGULATION
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
2005 Deficit Reduction Act: Fraud, Waste & Abuse, and Compliance Training 9/21/2018.
The Government’s Perspective
Training Objectives What is the Signature Partners MSSP ACO?
What Every Employee Should Know About Compliance.
ACC/Drake University Corporate Counsel Forum
Risk Management: why and how to protect your health center
Compliance, Ethics, and Audit
Presentation transcript:

When Pharmaceutical Marketing Crosses the Line: Best Practices For Investigation and Remediation

Government’s Emphasis on Health Care Enforcement  Health care fraud and abuse issues are a top government priority.  Cost of illegal health care schemes estimated at 10% of all health care spending.  Federal government has responded by declaring war on health care fraud and abuse.

FY 2000  More than $1.232 billion in criminal fines, civil judgments, settlements, and administrative sanctions.  3,350 exclusions from federal health care programs.  414 criminal convictions.  357 civil actions. Impact on the Heath Care Industry

Impact on the Health Care Industry (cont.) 10/01/01- 3/31/02  More than $728.7 million in civil settlements.  1,472 OIG-administered sanctions, in the form of program exclusions or civil actions on individuals and/or entities.  1,366 exclusions from health care programs. Source: OIG SemiAnnual Report: October 2001-March 31, 2002

Risk Areas 1)Intentional and Obvious Conduct Marketing the “spread,” and other AWP violations. Overcharging or mischarging on government contracts. Product substitution or delivery of nonconforming goods. Material misrepresentation regarding goods/services supplied. Re-sale of drug samples –PDMA concerns

Risk Areas (Cont.) 2)More Subtle Potential Violations Use of free goods, discounts to incent purchases – i.e. anti-kickback violations. Misuse of samples, grants, or educational funds. Improper allocation of indirect costs (overhead) to government. Misreporting actual levels of contract performance.

What Is My Corporation’s Potential Exposure?  Corporations are derivatively liable for most acts of employees and authorized agents under very broad civil and criminal standards. Civil : An employer is liable for acts of employees within the scope of their employment even without culpable intent by the employer. Criminal: A corporation is criminally liable if an officer, employee or agent commits a crime within the scope of his actual or apparent authority with the intent to benefit the corporation, regardless of whether the corporation actually benefited and regardless of whether the employee also intended to benefit himself.

What’s at Stake?  Monetary Fines/ Penalties / Sanctions  Exclusion from Health Care Participation  Criminal Convictions  Imprisonment  Highly publicized results

What’s at Stake? Example: Anti-Kickback Violations. Criminal statute Five years of jail Criminal fines of $250,000 Civil fines up to $50,000 and treble damages. Exclusion (criminal or civil)

How do we prepare for Government Investigations?

Step 1: Develop A Good Compliance Program  Key step in preparing for government investigations is to prevent government investigations.  Look to OIG Draft Compliance Guidelines for help on developing compliance program.

OIG Compliance Guidance: Seven Fundamental Elements of an Effective Compliance Program  Implementing written policies and procedures  Designating a compliance officer and committee  Conducting effective training and education  Developing effective lines of communication  Conducting internal monitoring and auditing  Enforcing standards through well-publicized disciplinary guidelines  Responding promptly to detected problems and undertaking corrective action.

Step 2: Familiarize with “Hot Topics” Where to Look? Statutes and Regulations Federal Anti-kickback statute State Anti-kickback statutes Stark II False Claims Act HIPAA Draft OIG Compliance Guidance Voluntary Guidelines OIG 2003 Workplan PhRMA Code AMA Guidelines on Gifts to Physicians from Industry OIG Advisory Opinions Other industry codes pending

I suspect a problem: Should I conduct an Internal Investigation?

The Benefits and Associated Risks of Conducting Internal Investigations  Benefits of Prompt and Thorough Internal Investigations Evaluating potential liability Gaining control Minimizing criminal exposure Minimizing civil exposure Minimizing likelihood of exclusion, debarment, or other adverse regulatory actions Public relations Sarbanes-Oxley Act Compliance

The Benefits and Associated Risks of Conducting Internal Investigations (cont.)  Associated Risks of Internal Investigations Increasingly difficult to preserve confidentiality Justice Department increasingly demanding disclosure of results of internal investigations, including privileged materials, in settlement negotiations with corporations  Holder Memorandum (June 1999)  “Timely and voluntary disclosure of wrongdoing” and “willingness to cooperate” are among specified factors prosecutors must consider in evaluating “proper treatment of corporate targets.”

The Benefits and Associated Risks of Conducting Internal Investigations (cont.)  Voluntary disclosure includes identifying culpable and knowledgeable personnel who may no longer work for the corporation and disclosing the findings of internal investigations.  An additional factor in the “completeness” of a corporation’s disclosure is whether it has agreed to waive the attorney-client and work product privileges, “both with respect to its internal investigation and with respect to communications between specific officers, directors, and employees and counsel.”

The Benefits and Associated Risks of Conducting Internal Investigations (cont.)  An additional related factor is whether the corporation appears to be protecting its culpable employees and agents. Factors to consider include:  advancing legal fees  joint defense arrangements  retaining employees without sanction

The Benefits and Associated Risks of Conducting Internal Investigations (cont.) Consequences of the DOJ’s Aggressive Stance on Privilege Waiver  Conflicts between corporation and employees  Chilling investigative inquiries/limiting reports  Deprives corporations of fully-informed legal advice  Vitiates individual’s Fifth Amendment protections  May disclose unknown wrongdoing  Collateral consequences of privilege waiver

Best Practices – Conducting Internal Investigations so as to Maximize Benefits and Minimize Risks  Inside vs. outside counsel  Maintaining confidentiality – cloak investigation with privilege  Witness interviews  Document review  Interacting with simultaneous government investigations Responding to document subpoenas Preparing employees for government interviews

Best Practices – Conducting Internal Investigations so as to Maximize Benefits and Minimize Risks (cont.)  Using experts  Representing employees – conflict concerns  Preparing the investigative report  Disclosure of the investigative report